[Translation] A multicenter, randomized, double-blind, placebo-controlled, dose-finding phase II clinical study was conducted to evaluate the efficacy and safety of Meifan Fuxin Liquid in the treatment of radiation-induced oral mucositis in patients with head and neck malignancies.

(1) 评价美蠊复新液治疗头颈部恶性肿瘤患者放射性口腔黏膜炎的有效性及安全性； (2) 探索美蠊复新液用于放射性口腔黏膜炎的最佳剂量，为Ⅲ期临床试验剂量选择提供依据； (3) 探索获益人群的中医辨证分型。

[Translation]

(1) To evaluate the effectiveness and safety of Meifan Fuxin solution in the treatment of radiation-induced oral mucositis in patients with head and neck malignancies; (2) To explore the optimal dose of Meifan Fuxin solution for radiation-induced oral mucositis and provide a basis for dose selection in phase III clinical trials; (3) To explore the TCM syndrome differentiation of the beneficiary population.

Start Date12 Jun 2024

Sponsor / Collaborator

Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd.

CTR20221962 / CompletedPhase 1

评价GD-N1702胶囊在健康受试者中单次及多次给药的安全性、耐受性、药代动力学和药效动力学的随机、双盲、安慰剂对照的Ⅰ期临床研究

[Translation] A randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of GD-N1702 capsules in healthy subjects

主要目的：评价GD-N1702胶囊在中国健康成年受试者中单次和多次口服给药后的安全性和耐受性。次要目的：评估GD-N1702胶囊单次和多次口服给药后的药代动力学（PK）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of GD-N1702 capsules after single and multiple oral administration in healthy Chinese adult subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of GD-N1702 capsules after single and multiple oral administration.

Start Date17 Oct 2022

Sponsor / Collaborator

Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

[+1]

CTR20222231 / CompletedPhase 1

评估消肿生肌口服液在中国健康成年受试者中的安全性、耐受性的I期临床研究。

[Translation] A phase I clinical study to evaluate the safety and tolerability of Xiaozhong Shengji Oral Liquid in healthy Chinese adult subjects.

评估消肿生肌口服液在中国健康成年受试者中的安全性、耐受性的Ⅰ期临床研究。

[Translation]

A phase I clinical study to evaluate the safety and tolerability of Xiaozhong Shengji Oral Liquid in healthy Chinese adult subjects.

Start Date01 Oct 2022

Sponsor / Collaborator

Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd.

100 Clinical Results associated with Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd.

0 Patents (Medical) associated with Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd.

Literatures (Medical) associated with Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd.

01 Jun 2024·Journal of Pharmaceutical and Biomedical Analysis

“Plant Golden” C. sativus: Qualitative and quantitative analysis of major components in stigmas and petals and their biological activity in vitro

Article

Author: Tan, Jin ; Song, Jiao ; Yang, Ming ; Geng, Funeng ; Pei, Jin ; Zhang, Dingkun ; Li, Xue ; Guan, Yongmei ; Ma, Hongyan

Crocus sativus L. (C. sativus) has its stigma as the main valuable part used. With extremely low production and high prices, stigma is considered a scarce resource. As a result, its petals, considered as by-products, are often discarded, leading to significant waste. We developed a UPLC-Q-Orbitrap HRMS method for qualitative analysis of stigmas and petals and a UHPLC-QQQ-MS/MS method for simultaneous quantification of 9 characteristic active compounds for the first time, and compared their biological activity in vitro. The results indicated that a total of 63 compounds were identified in the petals and stigmas. The content of flavonoids in the petals was significantly superior to that in the stigma, and the content of quercetin in the petals was 50 times higher than that in the stigma. The results of the in vitro evaluation of biological activity indicated that both the petals （•OH: IC₅₀=39.70 mg/mL; DPPH: IC₅₀=28.37 mg/mL; ABTS: IC₅₀=0.9868 mg/mL）and stigma （•OH: IC₅₀=34.41 mg/mL; DPPH: IC₅₀=38.99 mg/mL; ABTS: IC₅₀=3.194 mg/mL）demonstrated comparable antioxidant activities. However, the tyrosinase inhibitory activity in petals （IC₅₀=21.17 mg/mL） was weaker than that in stigma（IC₅₀=1.488 mg/mL）. This study provides a fast, reliable, and efficient analytical method that can be used for the quality assessment of petals as a natural resource and its related products in the food and pharmaceutical industries.

01 Jan 2024·Biomedicine & Pharmacotherapy

Ento-A alleviates DSS-induced experimental colitis in mice by remolding intestinal microbiota to regulate SCFAs metabolism and the Th17 signaling pathway

Article

Author: Zhao, Jie ; Wu, Taoqing ; Shen, Yongmei ; Wang, Dexiao ; Zhao, Yu ; Wang, Qian ; Zhang, Chenggui ; Gao, Pengfei ; Zhao, Hairong ; Liu, Heng ; Wu, Xiumei

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by changes in the metabolism of short chain fatty acids (SCFAs), dysregulation of gut microbiota, and an imbalance of Treg/Th17. Herein, we explore the effects of the Ento-A (an alcohol extract of Periplaneta americana L.) on a mouse model of UC. First, a chronic and recurrent UC model was constructed in BALB/c mice by 2.2% DSS administration. UC mice were continuously treated for 14 days with Ento-A (50, 100, 200 mg/kg, i.g.) or a negative control. Ento-A alleviated many of the pathological changes observed in UC mice, such as body weight loss, disease activity index, changes in colon length, and colonic mucosal damage index. Ento-A also decreased levels of proinflammatory cytokines (IL-1β, IL-6, IL-17A, and TNF-α), increased levels of anti-inflammatory cytokines (IL-10 and TGF-β1) and repaired the intestinal mucosal barrier. Additionally, Ento-A regulated the proportions of Th17 cells, and Treg cells in mesenteric lymph nodes harvested from treated mice (as assessed by Flow cytometry), and the expression levels of IL-17A and Foxp3 in colon (as assessed by immunohistochemistry). 16 S rRNA gene sequencing revealed that Ento-A regulated gut microbiota. GC-MS analysis demonstrated that Ento-A also restored SCFAs content in the intestinal tract. Finally, transcriptomic analysis revealed that Ento-A regulated the IL-17 signaling pathway. In summary, Ento-A regulates the diversity and abundance of intestinal flora in UC mice, enhancing the secretion of SCFAs, subsequently regulating the IL-17 signaling pathway, and ultimately repairing the intestinal mucosal barrier.

01 Sep 2023·Phytomedicine

Guizhi Shaoyao Zhimu granules attenuate bone destruction in mice with collagen-induced arthritis by promoting mitophagy of osteoclast precursors to inhibit osteoclastogenesis

Article

Author: Yao, Huan ; Li, Xueping ; Shen, Yongmei ; Xiang, Li ; Geng, Funeng ; Li, Fangqiong ; Liu, Weiwei ; Tan, Jin ; Huang, Yucheng ; Gao, Yongxiang

BACKGROUNDGuizhi Shaoyao Zhimu decoction, a traditional Chinese medicine formula used empirically for the treatment of rheumatoid arthritis (RA), has been shown to alleviate bone destruction in rats with collagen-induced arthritis (CIA).PURPOSEThe aim of this study is to characterize the effects of Guizhi Shaoyao Zhimu granules (GSZGs) on bone destruction in RA and the underlying mechanism.STUDY DESIGNA CIA arthritis model using DBA/1 mice. The animals were divided into a normal group; CIA model group; low, medium, and high-dose GSZG groups (3, 6, and 9 g/kg/day); and a methotrexate group (1.14 mg/kg/w). In vitro, a cytokine induced osteoclastogenesis model was established.METHODSAfter 28 days of treatment, the paw volume was measured, bone destruction was examined by micro-CT, and the generation of osteoclasts in bone tissue was evaluated via tartrate-resistant acid phosphatase (TRAP) staining. Furthermore, the inhibitory effect and underlying mechanism of action of GSZG on RANKL-induced osteoclastogenesis were investigated in vitro.RESULTSThe in vivo analyses demonstrated that the paw volume and degree of bone erosion of mice in the medium- and high-dose GSZG groups were significantly decreased compared to the CIA model group. In addition, GSZG treatment suppressed the excessive generation of osteoclasts in the bone tissue of CIA mice. In vitro, GSZG inhibited RANKL-induced osteoclastogenesis and osteoclast-mediated bone resorption. Specifically, it only inhibited the generation of osteoclast precursors (OCPs); it had no significant effect on the fusion of OCPs or maturation of osteoclasts. Finally, we showed that the inhibitory effect of GSZG on osteoclastogenesis was related to the promotion of PTEN-induced kinase protein 1 (PINK1)/Parkin pathway-mediated mitophagy of osteoclast precursors, which was verified using a PINK1 knockdown small interfering RNA in OCPs.CONCLUSIONThese findings indicate that GSZG is a candidate for the treatment of bone destruction in RA and provide a more detailed elucidation of the mechanism of GSZG anti-RA bone erosion, i.e., inhibition of the ROS/NF-κB axis through the PINK1/Parkin-mediated mitochondrial autophagic pathway to inhibit osteoclast precursor production, compared to the published literature.

100 Deals associated with Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd.

100 Translational Medicine associated with Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 29 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

IND Application

IND Approval

Phase 1 Clinical

Phase 2 Clinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SanQi LongXueJie Capsule	Cardiovascular Diseases More	Approved
Xiaozhong Shengji Oral Liquid	radiation oral mucositis More	Phase 2
GD-N1702	-	Phase 1
GD-N1801	Wounds and Injuries More	IND Approval
GD-N2203	-	IND Application

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis